Denali Therapeutics
DNLI
$18.56
Share price
0.54%
Change (1 day)
-38.58%
Change (1 year)
Denali Therapeutics (DNLI) - P/B ratio
P/B ratio as of June 2024 : 1.81
According to Denali Therapeutics
's latest financial reports the company has a price-to-book ratio of 1.81.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Denali Therapeutics - P/B ratio (from 2017 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 2.88 | -20.61% |
| 2022-12-31 | 3.62 | -35.99% |
| 2021-12-31 | 5.66 | -35.16% |
| 2020-12-31 | 8.73 | 105.74% |
| 2019-12-31 | 4.24 | 18.65% |
| 2018-12-31 | 3.58 | 21.07% |
| 2017-12-31 | 2.95 | |
| 2016-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Organovo ONVO | 2.05 | 13.61% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | 4.74 | 161.84% | 🇬🇧 UK |
 Novavax NVAX | -2.59 | -243.23% | 🇺🇸 USA |
 Novocure
NVCR | 6.67 | 268.70% | Jersey |